Evolution of Pulmonary Function in a Cohort of Patients with Interstitial Lung Disease and Positive for Antisynthetase Antibodies.

Montserrat Ixchel González-PérezJosé Guillermo Mejía-HurtadoDiana Isabel Pérez-RománIvette Buendía-RoldánMayra MejíaRamcés Falfan-ValenciaHeidegger N Mateos-ToledoJorge Rojas Serrano

Published in: The Journal of rheumatology (2019)

Improvement of pulmonary function was observed in 67% of the patients. Improvement was observed in all ASAB groups and occurred within 6 months after initiating medical treatment.

Keyphrases

interstitial lung disease
systemic sclerosis
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
healthcare
rheumatoid arthritis
idiopathic pulmonary fibrosis
peritoneal dialysis